PreveCeutical Launches Strategic Partnership With BioGene Therapeutics
PreveCeutical Launches Strategic Partnership With BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that it has signed a definitive agreement on the 29 October, 2024 (the "Agreement") to sell certain intellectual property assets (the "Assets") owned by itself and its affiliate, PreveCeutical (Australia) Pty Ltd. ("PreveCeutical Australia") to BioGene Therapeutics Inc., a wholly owned subsidiary of the Company ("BioGene") (the "Acquisition").
溫哥華,不列顛哥倫比亞省--(新聞發佈服務-新聞稿 - 2024年10月30日) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical"或"公司"), 一家開發創新預防性和治療性療法選擇的健康科學公司,利用有機和天然身份認同產品,很高興地宣佈已於2024年10月29日簽署了一份最終協議("協議"),出售其及其關聯公司PreveCeutical (澳大利亞) Pty Ltd.("PreveCeutical Australia")擁有的某些知識產權資產("資產")給公司的全資子公司BioGene Therapeutics Inc.("BioGene")("收購")。
Stephen Van Deventer, Chairman and CEO commented "We are extremely pleased that our Dual Gene Therapy program will advance as a singular entity, and we will retain new Scientists, Board of Directors and management who specialize in this medical field."
主席兼首席執行官Stephen Van Deventer評論稱"我們非常高興,我們的雙基因治療項目將作爲一個獨特實體前行,並且我們將保留在這一醫療領域專業的新科學家、董事會和管理團隊。"
The Assets that BioGene will acquire include (i) the intellectual property arising from the ongoing research program by UniQuest Pty Ltd. for PreveCeutical Australia, but excluding any improvements to the Background IP (as hereinafter defined); (ii) the option provided to PreveCeutical Australia to obtain a license of the Background IP (as hereinafter defined); and (iii) any other assets or intellectual property held by PreveCeutical and PreveCeutical Australia in connection with the commercialization of bio-responsive gene carrier-and-release systems for siRNA delivery in the treatment or prevention of diabetes and obesity. Background IP refers to all intellectual property developed at the University of Queensland in the research group of Dr. Harendra Parekh involving bioreducible amino acid derivatives, bioreducible peptide dendrimers synthesized from the amino acid derivatives, and methods and know-how for producing such bioreducible derivates and dendrimers.
BioGene將收購的資產包括(i)來源於UniQuest Pty Ltd.爲PreveCeutical Australia進行的正在進行的研究計劃的知識產權,但不包括對背景知識產權的任何改進;(ii)PreveCeutical Australia獲得背景知識產權許可的選項(如下定義);以及(iii)PreveCeutical和PreveCeutical Australia持有的關於生物響應型基因載體和釋放系統在糖尿病和肥胖治療或預防中的siRNA遞送的商業化的任何其他資產或知識產權。背景知識產權指的是在昆士蘭大學Harendra Parekh博士的研究小組中開發的所有知識產權,包括生物還原性氨基酸衍生物、從氨基酸衍生物合成的生物還原性肽樹狀聚合物,以及用於生產此類生物還原性衍生物和樹狀聚合物的方法和專有技術。
The aggregate purchase price for the Assets will be USD$1,353,227 (the "Purchase Price"), of which USD$500,000 will be paid in cash (the "Cash Payment") and the remaining paid by the allotment and issuance of 16,000,000 common shares (each, a "Consideration Share") in the capital of BioGene at a deemed price of USD$0.0533 per Consideration Share. The Cash Payment will be paid within 24 months. Additionally, BioGene will compensate PreveCeutical for third-party accounting costs incurred for its valuation and audit up to a maximum of $30,000.
資產的總購買價格爲1,353,227美元("購買價格"),其中500,000美元將以現金支付("現金支付"),其餘部分通過在BioGene的資本中按每股0.0533美元的議定價格分配併發行16,000,000普通股(每股稱爲"考慮股票")支付。現金支付將在24個月內支付。此外,BioGene將對PreveCeutical因其估值和審計而產生的第三方會計費用進行賠償,最高金額爲30,000美元。
PreveCeutical is committed to distributing a portion of the Consideration Shares to its shareholders (the "Distribution"), with the precise allocation of Consideration Shares to be distributed to be determined by the record date (as will be determined by PreveCeutical). At this time, PreveCeutical plans to allocate approximately 75% of the Consideration Shares for distribution, subject to the outcome of tax consultations and strategic planning for PreveCeutical's future. Shareholders who are registered on the record date will be eligible for a pro-rata distribution, whereby each shareholder will receive an allocation of Consideration Shares proportionate to their current shareholding in PreveCeutical. Shareholders can expect further details and confirmation of the exact share distribution numbers, as well as confirmation regarding the record date, in the coming weeks.
PreveCeutical致力於向其股東("分配")分配部分代考慮股份,代考慮股份的具體分配將由記錄日期(將由PreveCeutical確定)決定。目前,PreveCeutical計劃分配大約75%的代考慮股份供分配,視稅務諮詢和PreveCeutical未來戰略規劃結果而定。在記錄日期註冊的股東將有資格獲得按比例分配,每位股東將收到與其當前在PreveCeutical參股金融的持股成比例的代考慮股份分配。股東可以期待在接下來的幾周內獲得有關確切的股份分配數量以及有關記錄日期的進一步詳細信息和確認。
Closing of the Acquisition remains subject to, without limitation, receiving all necessary consents and approvals, as well as the satisfaction of various closing conditions as set forth in the Agreement.
收購的完成仍取決於諸如獲得所有必要的同意和批准以及符合協議中規定的各種關閉條件等事項。
About PreveCeutical
關於 PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical 是一家開發利用有機和自然同源產品進行預防和治療方案的健康科學公司。
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit , follow us on Twitter: and Facebook: .
PreveCeutical 旨在成爲預防性健康科學領域的領軍者,目前擁有五個研究和開發項目,包括:雙基因療法,旨在治療和預防糖尿病和肥胖病的研究; 溶膠凝膠項目; 用於治療各種疾病的天然相同肽; 作爲高度成癮性鎮痛劑(如嗎啡、芬太尼和羥考酮)替代品的非成癮性鎮痛肽; 以及用於治療患有腦震盪(輕度顱腦損傷)的運動員的治療產品。有關 PreveCeutical 的更多信息,請訪問,關注我們的推特: 和臉書: 。
On Behalf of the Board of Directors,
PreveCeutical Medical Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
董事會代表
Novo Resources Corp.
PreveCeutical 醫療公司。
「Stephen Van Deventer」
主席兼首席執行官
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
ir@PreveCeutical.com
如需更多信息,請聯繫:
Stephen Van Deventer
(604) 306-9669
ir@PreveCeutical.com
Forward-Looking Statements:
前瞻性聲明:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
本新聞稿包含前瞻性聲明。所有聲明,除了針對公司認爲、期待或預期未來可能發生的活動、事件或發展的歷史事實聲明之外,都是前瞻性聲明。本新聞稿中的前瞻性聲明包括關於收到對收購的監管和其他許可和批准的聲明;PreveCeutical、PreveCeutical澳大利亞和BioGene按照協議完成收購;PreveCeutical收到對分銷所必需的監管和其他許可和批准;以及PreveCeutical按上述內容完成分銷。前瞻性聲明反映管理層基於當前可用信息的當前期望,並可能受到一系列風險和不確定性的影響,這些風險和不確定性可能導致結果與前瞻性聲明中討論的結果有實質性差異,包括不利的市場條件和其他超出各方控制範圍的因素。儘管公司認爲前瞻性聲明中所包含的假設是合理的,但前瞻性聲明並不能保證未來業績,因此不應過度依賴這些聲明,因爲它們具有固有的不確定性。可能導致實際結果或事件與當前預期有實質不同的因素包括一般市場條件和公司無法控制的其他因素;影響PreveCeutical或BioGene未來結果或業績的不利影響生物技術或藥品行業的法規和政策;公司未能獲得收購和分銷所需的許可和批准;以及公司在稅收和業務諮詢後確定分銷不是最佳策略。公司明確聲明無意或義務更新或修訂任何前瞻性聲明,無論是基於新信息、未來事件還是其他原因,除非適用法律要求。
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其監管服務提供商(如加拿大證券交易所政策中所定義的那樣)不對本公告的充分性或準確性承擔任何責任。
譯文內容由第三人軟體翻譯。